Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms (Q38542600)

4 September 2017

1 reference

title

Cardiovascular risk with androgen deprivation therapy for prostate cancer: potential mechanisms (English)

1 reference

4 September 2017

1 reference

3

0 references

author name string

Åsa Tivesten

1

1 reference

4 September 2017

Jehonathan H Pinthus

2

1 reference

4 September 2017

Wilhelmina Duivenvoorden

4

1 reference

4 September 2017

Jan Nilsson

5

1 reference

4 September 2017

publication date

30 June 2015

1 reference

4 September 2017

1 reference

4 September 2017

volume

33

1 reference

4 September 2017

issue

11

1 reference

4 September 2017

page(s)

464-475

1 reference

Side effects of androgen deprivation therapy: monitoring and minimizing toxicity

4 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Metabolic and cardiovascular effects of androgen deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Metabolic complications of androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Androgen deprivation therapy, insulin resistance, and cardiovascular mortality: an inconvenient truth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Metabolic syndrome and prostate cancer: a review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Absolute and relative risk of cardiovascular disease in men with prostate cancer: results from the Population-Based PCBaSe Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Androgen-Deprivation Therapy and the Risk of Stroke in Patients With Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Androgen-deprivation therapy in treatment of prostate cancer and risk of myocardial infarction and stroke: a nationwide Danish population-based cohort study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Estrogen treatment for cancer of the prostate. Early results with 3 doses of diethylstilbestrol and placebo

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Cardiovascular outcomes in patients with locally advanced and metastatic prostate cancer treated with luteinising-hormone-releasing-hormone agonists or transdermal oestrogen: the randomised, phase 2 MRC PATCH trial (PR09).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Androgen deprivation therapy for localized prostate cancer and the risk of cardiovascular mortality

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Androgen deprivation therapy increases cardiovascular morbidity in men with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Androgen-deprivation therapy for nonmetastatic prostate cancer is associated with an increased risk of peripheral arterial disease and venous thromboembolism

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Impact of androgen deprivation therapy on cardiovascular disease and diabetes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Androgen deprivation therapy for prostate cancer is associated with cardiovascular morbidity and mortality: a meta-analysis of population-based observational studies

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Quantifying observational evidence for risk of fatal and nonfatal cardiovascular disease following androgen deprivation therapy for prostate cancer: a meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Cardiovascular mortality after androgen deprivation therapy for locally advanced prostate cancer: RTOG 85-31.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Androgen deprivation therapy for prostate cancer does not increase cardiovascular mortality in the long term

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Cardiovascular Safety of Degarelix: Results From a 12-Month, Comparative, Randomized, Open Label, Parallel Group Phase III Trial in Patients With Prostate Cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Gonadotropin-releasing hormone blockers and cardiovascular disease risk: analysis of prospective clinical trials of degarelix

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Hormonal therapy use for prostate cancer and mortality in men with coronary artery disease-induced congestive heart failure or myocardial infarction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Androgen-suppression therapy for prostate cancer and the risk of death in men with a history of myocardial infarction or stroke

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

The cardiovascular risk of gonadotropin releasing hormone agonists in men with prostate cancer: an unresolved controversy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Management of complications of androgen deprivation therapy in the older man.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

High serum testosterone is associated with reduced risk of cardiovascular events in elderly men. The MrOS (Osteoporotic Fractures in Men) study in Sweden

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Hypogonadism as a risk factor for cardiovascular mortality in men: a meta-analytic study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Androgen receptor-dependent and independent atheroprotection by testosterone in male mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Testosterone: a vascular hormone in health and disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Testosterone up-regulates scavenger receptor BI and stimulates cholesterol efflux from macrophages

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Adverse events associated with testosterone administration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Androgens, angiogenesis and cardiovascular regeneration

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Atherosclerotic plaque progression and vulnerability to rupture: angiogenesis as a source of intraplaque hemorrhage

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Androgen receptor promotes sex-independent angiogenesis in response to ischemia and is required for activation of vascular endothelial growth factor receptor signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Testosterone Increases Human Platelet Thromboxane A2 Receptor Density and Aggregation Responses

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Neutropenia with impaired host defense against microbial infection in mice lacking androgen receptor

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Which white blood cell subtypes predict increased cardiovascular risk?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

GnRH-I and GnRH-II have differential modulatory effects on human peripheral blood mononuclear cell proliferation and interleukin-2 receptor gamma-chain mRNA expression in healthy males

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Pathology of the vulnerable plaque

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Cytokines and growth factors positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Apoptosis of vascular smooth muscle cells induced by in vitro stimulation with interferon-gamma, tumor necrosis factor-alpha, and interleukin-1 beta

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Macrophages heterogeneity in atherosclerosis - implications for therapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Macrophage plasticity in experimental atherosclerosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

GnRH antagonist associates with less adiposity and reduced characteristics of metabolic syndrome and atherosclerosis compared with orchiectomy and GnRH agonist in a preclinical mouse model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Update on acute coronary syndromes: the pathologists' view

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Immunoidentification of gonadotropin releasing hormone receptor in human sperm, pituitary and cancer cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Gonadotropin-releasing hormone receptor expression in the human prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

The Heart: A Novel Gonadotrophin-Releasing Hormone Target

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Expression of gonadotropin-releasing hormone and gonadotropin-releasing hormone receptor mRNAs in various non-reproductive human tissues

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

A gene atlas of the mouse and human protein-encoding transcriptomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Anti-human FSH receptor monoclonal antibodies: immunochemical and immunocytochemical characterization of the receptor.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Expression of Follicle-Stimulating Hormone Receptor in Tumor Blood Vessels

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Serum bioactive and immunoreactive follicle-stimulating hormone in prostatic cancer patients during gonadotropin-releasing hormone agonist treatment and after orchidectomy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients with Coronary and other Atherosclerotic Vascular Disease: 2011 update: a guideline from the American Heart Association and American College of Cardiology Foundation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Toremifene improves lipid profiles in men receiving androgen-deprivation therapy for prostate cancer: interim analysis of a multicenter phase III study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

Intermittent versus continuous androgen deprivation in prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016/J.UROLONC.2015.05.030

10.1016/J.UROLONC.2015.05.030

7 January 2021

Identifiers

DOI

1 reference

4 September 2017

1 reference